tiprankstipranks
Advertisement
Advertisement

Dr. Reddy’s Board to Weigh Final FY 2025–26 Dividend on April 16 Disclosure

Story Highlights
  • Dr Reddy’s filed a Form 6-K on April 16, 2026, reaffirming its compliance as a foreign private issuer with U.S. disclosure rules.
  • The company notified stock exchanges that its board will consider recommending a final dividend for FY 2025–26, signaling potential shareholder payouts.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Dr. Reddy’s Board to Weigh Final FY 2025–26 Dividend on April 16 Disclosure

Claim 55% Off TipRanks

Dr Reddy’s Laboratories ( (RDY) ) just unveiled an update.

On April 16, 2026, Dr. Reddy’s Laboratories filed a Form 6-K with the U.S. Securities and Exchange Commission, providing an update to investors as a foreign private issuer under the Securities Exchange Act of 1934. The filing, signed by the company secretary, confirms ongoing compliance and disclosure practices for its overseas listings.

In a concurrent communication to Indian and international stock exchanges dated April 16, 2026, the company announced that its Board of Directors will meet to consider, among other items, a proposal to recommend a final dividend for the financial year 2025–26. The move signals potential shareholder returns for the year just ended and underscores the company’s attention to capital allocation and investor communication across its multiple trading venues.

The most recent analyst rating on (RDY) stock is a Buy with a $16.90 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories is an India-based global pharmaceutical company focused on generic medicines, active pharmaceutical ingredients and branded formulations across key markets including India and the U.S. The company is listed on the National Stock Exchange of India, BSE, the New York Stock Exchange and NSE IFSC, reflecting its diversified investor base and international market presence.

Average Trading Volume: 2,186,145

Technical Sentiment Signal: Sell

Current Market Cap: $10.89B

Learn more about RDY stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1